Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, first in human (FIH), randomised, double-blind, placebo-controlled, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of the recombinant respiratory syncytial virus vaccines (BARS13) when administered intramuscularly (IM) to healthy adult volunteers.

Trial Profile

A Phase I, first in human (FIH), randomised, double-blind, placebo-controlled, dose-escalation study to evaluate safety, reactogenicity and immunogenicity of the recombinant respiratory syncytial virus vaccines (BARS13) when administered intramuscularly (IM) to healthy adult volunteers.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2019

At a glance

  • Drugs Respiratory syncytial virus vaccine (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 23 Jan 2019 According to Australian New Zealand Clinical Trials Registry record, recruitment completion is expected on 2/19/2019.
    • 18 Jan 2019 Planned End Date changed from 15 May 2019 to 19 Jun 2019.
    • 13 Nov 2018 Planned End Date changed from 19 Apr 2019 to 15 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top